Novo Nordisk faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy to expand market access and defend share. NVO's long-term upside relies on broadening ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈